Table 3 Ongoing phase III trials for durvalumab in non-small cell lung cancer
From: Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Identifier | Title | Interventions | Study design | Population | Primary endpoint | Secondary endpoint | Status | Primary Completion |
|---|---|---|---|---|---|---|---|---|
NCT03800134 | A study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small cell lung cancer (AEGEAN) | Durvalumab + platinum-based chemotherapy Placebo + platinum-based chemotherapy | Randomized parallel trial | Resectable stage IIA–IIIB NSCLC | MPR | pCR, OS, DFS | Recruiting | 27-Jul -20 |
NCT03519971 | Study of durvalumab given with chemoradiation therapy in patients with unresectable non-small cell lung cancer (PACIFIC2) | Durvalumab + platinum-based chemotherapy and radiation Placebo + platinum-based chemotherapy and radiation | Randomized parallel trial | Unresectable locally advanced stage III NSCLC | PFS, ORR | OS, DOR, PFS2 | Recruiting | 30-Sep-20 |
NCT02273375 | Double blind placebo controlled study of adjuvant MEDI4736 in completely resected NSCLC | Durvalumab Placebo | Randomized parallel trial | Stage IB (> 4 cm) to IIIA NSCLC after complete surgical resection | DFS | OS, LCSS | Recruiting | Jan-23 |
NCT03706690 | A study of durvalumab as consolidation therapy in non-small cell lung cancer patients (PACIFIC5) | Durvalumab Placebo | Randomized parallel trial | Unresectable locally advanced stage III NSCLC | PFS | OS, ORR, DOR | Recruiting | 25-Mar-21 |
NCT03164616 | Study of durvalumab + tremelimumab with chemotherapy or durvalumab with chemotherapy or chemotherapy alone for patients with lung cancer (POSEIDON) | Durvalumab + tremelimumab Durvalumab monotherapy + SoC SoC chemotherapy alone | Randomized parallel trial | Untreated advanced NSCLC without activating EGFR mutation or ALK fusions | PFS, OS | ORR, DOR, | Recruiting | 30-Sep-19 |
NCT03003962 | Study of durvalumab alone or chemotherapy for patients with advanced non small-cell lung cancer | Durvalumab SoC chemotherapy | Randomized parallel trial | Untreated advanced PD-L1 positive NSCLC without EGFR mutation and ALK rearrangement | OS | ORR, DOR, PFS | Active, not recruiting | 30-Sep-19 |
NCT02453282 | Phase III open label first line therapy study of MEDI 4736 (durvalumab) with or without tremelimumab versus soc in non-small-cell lung cancer (MYSTIC) | Durvalumab Durvalumab + tremelimumab SoC chemotherapy | Randomized parallel trial | Untreated advanced NSCLC without activating EGFR mutation or ALK fusions | OS, PFS | ORR | Active, not recruiting | 4-Oct-18 |
NCT02542293 | Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | Durvalumab + tremelimumab SoC chemotherapy | Randomized parallel trial | Untreated advanced NSCLC without activating EGFR mutation or ALK fusions | OS | PFS, ORR, DOR | Active, not recruiting | 22-Aug-19 |